January 7, 2022
Cascadia Capital, an investment bank serving middle market clients globally, today announced it acted as the exclusive financial advisor to Pacific Northwest Fertility (“PNWF”), a leading fertility provider in Greater Seattle, in a partnership with Ivy Fertility (“Ivy”), a nationally and internationally recognized innovator in the field of advanced reproductive technologies, in-vitro fertilization, and third-party reproduction that is backed by InTandem Capital Partners.
This follows InTandem Capital’s investments in San Diego Fertility Clinic (“SDFC”) in February and Reproductive Partners Medical Group (“RPMG”) in May, and continues in the creation of a leading fertility services platform. The companies rank among the top reproductive medical centers in the United States . Cascadia Capital was the exclusive advisor to both RPMG and SDFC, as well.
PNWF is a world-class reproductive center committed to advancing the science of reproduction with the sole purpose of building families with compassion and individualized care. The collective experience of the physicians, embryologists, and the entire team at PNWF has solidified its position as a visionary in the field. Since 2005, PNWF has been a leader in all aspects of fertility care including creating and growing SIMPLIFY, its own donor egg bank.
“The partnership between Pacific Northwest Fertility and Ivy is a unique opportunity to expand the platform’s geography on the west coast and provides a strategic foothold for the practices. The synergy with the other practices made for a compelling fit,” noted Kevin Cable, Managing Director in Cascadia’s Healthcare practice group.
“Cascadia Capital used their considerable resources and expertise in the fertility market to help us create this strategic partnership. We are excited for this opportunity to expand and improve patient care,” said Dr. Lorna Marshall, co-founder of PNWF.
Cascadia Capital’s Healthcare team was incredibly active in 2021, closing 11 transactions during the year, including four transactions in the fertility sector. Other select prior healthcare industry transactions include Tegria’s acquisition of Cumberland, BregalSagemount’s investment in DentalXChange, the acquisition of SonicBoom by Premise Health and the sale of Mimic Technologies to Surgical Science.
For more information about this transaction, please contact the Cascadia Capital deal team:
Managing Director and Co-Founder
Senior Vice President
Or other senior members of the Cascadia Healthcare team:
Please complete the form below to access this resource.